Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease

Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria CAMBRIDGE, England, March 21, 2024 /PRNewswire/ — Mission Therapeutics (“Mission” or the “Company”), a…